Search
Lorazepam
go.drugbank.com/drugs/DB00186ApprovedInvestigational[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
Products: Lorazepam Injection USP, Lorazepam Injection, USPSodium ferric gluconate complex
go.drugbank.com/drugs/DB09517ApprovedSodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. … The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography.
Products: Sodium Ferric Gluconate Complex in SucroseZoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigational[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712] … Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].
Products: ZONDRA® SOLUCION INYECTABLE, ATAZOL 4 MG/5 ML IV İNFÜZYONLUK ÇÖZELTİ, 1 ADETRemdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[A222398] Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. … [L39640] Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.[L22619]
Products: VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALDecitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigationalIt was first marketed under the name Dacogen®.[L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.
Products: DACOGEN 50 MG IV KONSANTRE İNFÜZYONLUK ÇÖZELTİ İÇİN TOZ, DESİTAB 50 MG IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 ADETTerlipressin
go.drugbank.com/drugs/DB02638ApprovedInvestigationalTerlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor.[A2601] It is a prodrug of [lypressin], or lysine vasopressin. … [A2601, A2602, A2603, A2604, A2605] It was also studied in hepatorenal syndrome (HRS) and variceal bleeding.[A252672] The drug was first approved by the FDA in September 2022.[L43217]
Categories: Vasopressin Receptor AgonistProducts: GLYPRESSIN 1 MG/8,5 ML IV ENJEKSIYONLUK COZELTI ICEREN AMPUL, 5 ADET, GLYPRESSIN 1 MG IV ENJEKSIYONLUK TOZ IÇEREN FLAKON VE ÇÖZÜCÜ AMPUL, 1 ADETOxybuprocaine
go.drugbank.com/drugs/DB00892ApprovedInvestigationalOxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology.
Mixtures: Fluorescein Sodium & Benoxinate Hydrochloride Ophthalmic Solution, USPProducts: Benoxinat 1% - Lösung zur Anästhesie in der Oto-Rhino-LaryngologieRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165mlInterferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalIt is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. … The amino acid sequence is identical to that of natural human interferon beta.
Categories: Interferon Type IProducts: Rebif Solution for Injection in Cartridge 22mcg/0.5ml, Rebif Solution for Injection in Cartridge 44mcg/0.5mlTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic … Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent
Categories: HER2 Receptor Antagonists, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsProducts: KADCYLA 100 MG IV INFUZYONLUK COZELTI KONSANTRESI ICIN TOZ, KADCYLA 160 MG IV INFUZYONLUK COZELTI KONSANTRESI ICIN TOZ